1. Clinical Overview

Molecule: Mechanosensitive splice variant of IGF-1 (IGF-1 Ec Isoform), produced locally in muscle after mechanical overload/injury.

Classification: Acute-phase muscle regeneration peptide • Satellite cell activator • Locally-acting IGF-1 isoform • Anti-apoptotic repair molecule • Hypertrophy/recovery peptide

MGF vs IGF-1 LR3

Property	MGF	IGF-1 LR3
Primary role	Repair & satellite cell activation	Growth & hypertrophy
Timing	Post-injury / post-training	Daily systemic
Half-life	Short (minutes–hours)	Long (20–30 hours)
Local vs systemic	Local/regional	Systemic
Best use	Injury, repair	Hypertrophy, metabolism

Together, MGF + IGF-1 LR3 form a powerful two-phase anabolic/repair stack replicating natural muscle physiology.

2. Mechanisms of Action

2.1 Satellite Cell Activation (Primary)

One of the strongest known satellite cell activators: muscle stem-cell proliferation, damaged fiber repair, new myonuclei formation. Cannot be replicated by IGF-1 alone.

2.2 Local Muscle Repair Signal

Functions locally/autocrinely: released only in damaged/stressed muscle, signals rapid repair, prevents apoptosis.

2.3 IGF-1 Axis Synergy

MGF → satellite cell activation → IGF-1 LR3 → differentiation + hypertrophy. Gold-standard two-phase sequence.

2.4 Anti-Apoptotic & Protective

Reduces caspase activity, protects cells after overexertion, reduces muscle fibrosis.

2.5 Age-Related Decline Prevention

MGF production declines with age → sarcopenia, slower recovery, reduced stem-cell activity. Supplementation re-establishes youthful repair.

3. Evidence-Supported Applications

3.1 Muscle Injury Recovery

Tears, chronic strains, contusions, post-surgical repair, overtraining damage. Often combined with BPC-157 & TB-500.

3.2 Tendon, Ligament & Joint

Progenitor cell activation, collagen repair, joint soft-tissue healing.

3.3 Hypertrophy & Athletic Development

Post eccentric loading, high-volume workouts, novel training phases. Enhanced lean mass, strength, training frequency capacity.

3.4 Post-Surgical Atrophy Prevention

Mitigates muscle loss after immobilization, orthopedic surgery, long rehab windows.

3.5 Anti-Aging / Sarcopenia

Older adults, frailty, slow recovery, low satellite-cell activity. Counters age-driven anabolic resistance.

4. Administration & Protocols

4.1 IM MGF (Preferred)

Localized: 100–300 mcg IM near target muscle, post-training/injury, 1–2×/day
Injury Repair: 200–300 mcg IM daily × 10–20 days + TB-500 & BPC-157

4.2 SC MGF

200–400 mcg SC daily, post-training window. For larger areas or systemic repair.

4.3 PEG-MGF (Extended Half-Life)

200–400 mcg SC, 2–3×/week. Half-life extended to 12–24 hours via PEGylation.

4.4 Two-Phase MGF → IGF-1 LR3 Protocol

Phase 1 (MGF): 100–300 mcg IM/SC immediately post-training → satellite cell proliferation
Phase 2 (IGF-1 LR3): 20–80 mcg SC 1–2 hours after MGF → hypertrophy & differentiation
Never combine simultaneously — they counter-regulate each other.

5. Combination Therapy (Peptide Protocol Portal Synergy)

MGF + IGF-1 LR3: Gold standard — most powerful hypertrophy + repair stack
MGF + BPC-157 + TB-500: Ultimate injury-repair triad (stem cells + angiogenesis + remodeling)
MGF + CJC-1295 + GHRPs: Enhanced GH environment + IGF axis + recovery
MGF + SS-31 / MOTS-c: Mitochondrial repair for athletes/older adults
MGF + AOD-9604: Body recomposition — fat loss + muscle retention

6. Clinical Decision Trees

Decision Tree 1 — Should MGF Be Used?

Recovering from muscle injury? → YES

Goal: hypertrophy or rapid recovery? → YES

Post-surgery with atrophy risk? → YES

Elderly with sarcopenia? → YES

Systemic fat loss priority? → MGF is secondary

Prefers IM over SC? → IM gives best localized benefits

Decision Tree 2 — Dose Selection

Localized injury/surgery → 200–300 mcg IM daily

Post-training hypertrophy → 100–200 mcg IM post-workout

Systemic recovery → 200–400 mcg SC daily

Convenience (PEG-MGF) → 200–400 mcg SC 2–3×/week

7. Integrated Treatment Archetypes

Archetype A — Muscle Tear / Sports Injury

Systemic: MGF 200–300 mcg IM daily + TB-500 weekly + BPC-157 daily + NAD+

Outcome: Accelerated regeneration, reduced scar formation.

Archetype B — Hypertrophy / Strength

Systemic: MGF post-training + IGF-1 LR3 1–2 hrs after + CJC-1295/Ipamorelin nightly

Outcome: Superior hypertrophy and rapid repair.

Archetype C — Anti-Aging / Sarcopenia

Systemic: MGF 200 mcg SC daily + MOTS-c weekly + SS-31 + RECOVER™

Outcome: Restored strength, vitality, muscle tone.

Archetype D — Post-Surgical Preservation

Systemic: MGF daily SC/IM + TB-500 weekly + BPC-157 daily + IGF-1 LR3 low dose

Outcome: Reduced atrophy, faster return-to-function.

8. Expected Clinical Timeline

Day 1–3: Improved soreness, reduced stiffness
Week 1–2: Faster recovery
Week 2–4: Visible hypertrophy
Week 4–8: Significant functional gains
Long-term: Enhanced muscle density and resilience

9. Contraindications

Absolute

Active cancer (especially IGF-driven)
Pregnancy
Breastfeeding

Relative

Diabetes (monitor glucose)
Severe cardiac disease
Retinopathy
Uncontrolled hypertension

10. Adverse Effects

Most common: injection site soreness, water retention (mild), temporary lethargy, headache. Less common: hypoglycemia (with IGF-1 LR3), joint aches, appetite fluctuations.

11. Monitoring

IGF-1 levels
Fasting glucose
Muscle strength metrics
Injury healing progression
Body composition
Training tolerance

Legal Disclaimer

This document is provided solely for educational and informational purposes. MGF and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — MGF Clinical Reference Guide

Foundational Discovery & Identification

1. Yang, S. Y., Goldspink, G. IGF-1 isoforms in muscle growth and repair. Acta Physiol Scand, 167(4), 301–309 (1999).

2. Goldspink, G. Gene expression in muscle adaptation: MGF. Med Sci Sports Exerc, 35(5), 716–723 (2003).

3. Hill, M., & Goldspink, G. MGF expression following exercise. J Physiology, 548(2), 769–780 (2003).

4. Yang, S., et al. MGF mRNA as early response to mechanical stimuli. J Physiology, 516(2), 573–583 (1999).

Hypertrophy, Repair & Satellite Cells

5. McKoy, G., et al. MGF activates satellite cells. J Physiology, 547(2), 531–538 (2003).

6. Adams, G. R. IGF-1 and MGF in skeletal hypertrophy. J Endocrinology, 152(1), 1–2 (1997).

7. Musarò, A., & Rosenthal, N. IGF-1 isoforms in muscle regeneration. Nature, 400(6744), 581–585 (1999).

8. Zeng, M., et al. MGF supports myotube survival. Mol Cell Biochem, 337(1–2), 55–63 (2010).

9. Philippou, A., et al. MGF vs IGF-1Ea in resistance exercise. Am J Physiol Endocrinol Metab, 284(4), E627–E633 (2003).

Aging & Sarcopenia

10. O'Neill, B. T., et al. Declining IGF-1 isoforms in aging muscle. Aging Cell, 15(3), 439–449 (2016).

11. Kandalla, P. K., et al. Age-related MGF downregulation. Mech Ageing Dev, 134(7–8), 356–366 (2013).

12. Barton-Davis, E. R., et al. MGF reverses age-related wasting. Nature, 402, 200–203 (1999).

Tendon & Connective Tissue

13. Heinemeier, K. M., et al. MGF in tendons under loading. J Appl Physiol, 106(2), 575–581 (2009).

14. Paerhati, S., et al. MGF improves tendon fibroblast proliferation. Connect Tissue Res, 54(5), 339–347 (2013).

Bone & Orthopedic

15. Yi, C., et al. MGF promotes osteoblast proliferation. J Bone Miner Res, 18(4), 703–711 (2003).

16. Khorshidi, M., et al. MGF improves bone repair. Bone, 45(5), 885–893 (2009).

17. Brodt, M. D., et al. Mechano-sensitive IGF-1 isoforms in skeletal tissue. J Bone Miner Res, 26(1), 131–140 (2011).

Neuroprotection & CNS

18. Dluzniewska, J., et al. MGF protects neurons from β-amyloid. J Neurochem, 91(1), 34–43 (2004).

19. D'Ercole, A. J., et al. IGF-1 isoforms in CNS neuroregeneration. Trends Neurosci, 25(8), 349–355 (2002).

20. Quesada, A., et al. MGF enhances neuronal survival after ischemia. Neurosci Lett, 423(3), 181–185 (2007).

Cardiac & Anti-Apoptotic

21. Shavlakadze, T., Grounds, M. MGF in cardiac tissue repair. Circulation, 112(20), 3124–3133 (2005).

22. Siwik, D. A., et al. MGF reduces cardiomyocyte apoptosis. Cardiovasc Res, 89(1), 67–75 (2011).

23. Loudon, B. L., et al. IGF-1 isoforms in cardiovascular tissue. J Mol Cell Cardiol, 49(3), 398–404 (2010).

Mechanotransduction & Gene Expression

24. Carroll, A. M., & Goldspink, G. MGF as mechanotransduction gene. Pflügers Archiv, 452(3), 332–340 (2006).

25. Bickel, C. S., et al. IGF-1 splice variants after resistance training. Eur J Appl Physiol, 101(3), 353–360 (2007).

Pharmacologic & Delivery

26. Adams, G. R. MGF peptide analogues in regenerative therapy. Sports Medicine, 34(14), 953–970 (2004).

27. Kandalla, P. K., et al. MGF peptide delivery enhances regeneration. Growth Horm IGF Res, 22(3–4), 143–150 (2012).

28. Liu, J. P., & Baker, J. IGF-1 receptor dependence of MGF. Endocrine Reviews, 26(5), 916–944 (2005).

Metabolic & Systemic

29. Clemmons, D. R. IGF-1 in muscle and metabolic health. Endocrine Reviews, 34(1), 1–19 (2013).

30. Yakar, S., et al. IGF-1 regulates metabolic function. PNAS, 98(18), 10403–10408 (2001).

MGF (Mechano Growth Factor)